Monday, April 28, 1997
When treating bacterial
infections, especially in patients whose immune systems are already
compromised, time is of the essence. Knowledge of what bacteria have infected
the patient, and which antibiotic to prescribe, must come as early as possible.
In the best-case scenario, such information would be at a physician's
fingertips even before life-threatening symptoms arise in the patient.
Infectech Inc. is doing
its part to modernize the detection of infectious bacteria and make such
information readily accessible. CEO and co-founder Mitchell Felder, along with
chairman and co-founder Robert Ollar, have developed assays designed to rapidly
detect and identify infectious bacterial strains as well as determine which
antibiotic or combination of antibiotics will curtail bacterial growth.